Treatment extends life for men with prostate cancer

Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

A new treatment has been shown to extend the lifespans of men with advanced prostate cancer by as much as one year, researchers said Sunday.

The study involved 790 men who were diagnosed with , meaning the disease had spread beyond the prostate.

By adding the chemotherapy drug docetaxel to standard , known as (ADT), fewer patients died and many lived longer.

After 29 months, 136 men had died in the ADT alone group and 101 in the combination group.

The median, or midpoint, overall survival for the ADT group was 44 months, while those who also received docetaxel lived 57.6 months.

ADT is an effective therapy but eventually most patients become resistant to it, allowing the cancer to spread.

Some 30,000 men die of hormone-resistant prostate cancer each year in the United States.

"Hormone has been a standard treatment for prostate cancer since the 1950s," said lead study author Christopher Sweeney of the Dana Farber Cancer Institute in Boston, Massachusetts.

"This is the first study to identify a strategy that prolongs survival in newly diagnosed metastatic ," he added, describing the benefit as "substantial."

The research was presented at the American Society of Clinical Oncology annual conference.

"These results demonstrate how we can use 'old tools' in new, more powerful ways to improve and extend patients' lives," said ASCO president Clifford Hudis.

add to favorites email to friend print save as pdf

Related Stories

ASCO: No benefit for immediate ADT after PSA-only relapse

May 22, 2014

(HealthDay)—For men with a prostate-specific antigen (PSA)-only-based relapse after prostate surgery or radiation therapy, there seems to be little or no survival benefit for immediate initiation of androgen ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.